Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly completes offer for ImClone

This article was originally published in Scrip

Executive Summary

Lillyhas completed its tender offer for all of ImClone Systems's outstanding shares.. The $70 per share cash offer, conducted through Lilly's subsidiary Alaska Acquisition, expired at midnight EST on November 20th. Around 85.4 million shares were tendered, representing 95.5% of ImClone's issued and outstanding shares. Lilly plans to complete the acquisition through a short-form merger on or by Monday. All outstanding shares of ImClone's common stock not already purchased by Alaska will be converted into the right to receive $70 per share in cash. The offer's completion marks the end of one of this year's most headline-grabbing takeover stories after Bristol-Myers Squibbfailed to acquire ImClone. Lilly subsequently emerged as a mystery bidder and succeeded in offering what chairman Carl Icahn believed was an acceptable bid (Scrip Online, October 7th, 2008).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel